[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335518-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335518-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","icos-expressing-car-t-cells-mediate-durable-eradication-of-triple-negative-breast-cancer-and-metastasis","ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis","","Triple-negative breast cancer (TNBC) remains difficult to treat due to limited effectiveness of conventional surgery, radiation, and chemotherapy, with outcomes shaped by recurrence and metastasis. This study investigates the inducible costimulator (ICOS) axis, focusing on how ICOS expression and its ligand ICOSL influence antitumor immunity and T-cell differentiation. Using TNBC models, the work evaluates ICOS-enhanced B7H3-CAR-T cells and tests mechanisms by regulating ICOSL on tumor cells. Results show ICOSL is elevated in TNBC, associates with poor prognosis, and supports durable cytotoxicity and metastasis eradication in vivo, improving survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/icos-expressing-car-t-cells-mediate-durable-eradication-of-triple-negative-breast-cancer-and-metastasis/335518/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/icos-expressing-car-t-cells-mediate-durable-eradication-of-triple-negative-breast-cancer-and-metastasis/335518.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical problem does the study address in triple-negative breast cancer?","Question",{"text":63,"@type":64},"The study addresses limited eradication of TNBC by conventional therapies, which often leads to systemic recurrence and metastasis and results in poor prognosis and reduced survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the ICOS-enhanced CAR-T cells designed and evaluated?",{"text":68,"@type":64},"ICOS-enhanced B7H3-CAR-T cells were generated using third-generation CAR-T technology with heightened ICOS expression and targeting B7H3. Their cytotoxicity and durability were tested in TNBC xenograft and metastasis models, including in vitro and in vivo settings.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does ICOSL expression on TNBC cells play?",{"text":72,"@type":64},"Elevated ICOSL expression in TNBC tumor tissues correlated with worse survival. Manipulating ICOSL via overexpression or CRISPR/Cas9-mediated knockout significantly altered the function of ICOS-B7H3-CAR-T cells, indicating ICOSL level is critical for enhanced antitumor effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335518,1790650801,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Original research  \nTo cite: Cao L, Peng H, Chen Y, et al. ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis. Journal for ImmunoTherapy of Cancer 2024;12:e010028 . doi:10.1136/jitc-2024-010028  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-010028](jitc-2024-010028)) .  \nLC, HP, YC and BX contributed equally.  \nAccepted 17 October 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nXinxin Chen;  \n[chenxinxin@gzhmu.edu.cn](chenxinxin@gzhmu.edu.cn)  \nHui Zhang;  \n[zhangh92@mail.sysu.edu.cn](zhangh92@mail.sysu.edu.cn)  \nHaiyan Ye;  \n[yehaiyan@gdph.org.cn](yehaiyan@gdph.org.cn)  \nFei Yu; [yufei@gdph.org.cn](yufei@gdph.org.cn)  \nICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis  \nLixue Cao  ,1 Haojie Peng,2,3 Yanzhen Chen,4 Baijin Xia,1,5 Tao Zeng,2 Jialing Guo,1 Fei Yu  ,1 Haiyan Ye,4 Hui Zhang  ,6 Xinxin Chen  2  \nABSTRACT  \nBackground The failure of conventional therapies and the propensity for recurrence and metastasis make triple-negative breast cancer (TNBC) a formidable challenge with grim prognoses and diminished survival rates. Immunotherapy, including immune checkpoint blockade and chimeric antigen receptor (CAR)-T cell therapy, presents innovative and potentially more effective strategies for addressing TNBC. Within this context, the inducible costimulator (ICOS), a member of the CTLA4/ CD28 family, plays a crucial role in regulating immune responses and T-cell differentiation by binding to its ligand ICOSL. However, the impact of the ICOS/ICOSL axis on cancer varies.  \nMethods In this study, immunohistochemistry was conducted to examine the expression level of ICOSL in TNBC tumor tissues. We developed ICOS-enhanced B7H3-CAR-T cells (ICOS-B7H3-CAR) using the third-generation  \nCAR-T cell technology, which featured magnified ICOS expression and targeted the B7H3 antigen. Xenograft and metastasis models of TNBC were conducted to examine the cytotoxicity and durability of CAR-T cells in tumors. Overexpression and CRISPR/Cas9-mediated knockout (KO) techniques were employed to regulate the expression of ICOSL on TNBC cell lines.  \nResults Notably, we observed elevated ICOSL expression in TNBC tumor tissues, which correlated with poor survival prognosis in patients with TNBC. Compared with conventional B7H3-CAR-T cells, ICOS-B7H3-CAR-T cells significantly inhibited the tumor growth of TNBC cells both in vitro and in vivo, accompanied by increased secretion of cytokines such as interferon gamma and tumor necrosis factor alpha. Furthermore, the in vivo experiments illustrated that ICOS-B7H3-CAR-T cells exhibited prolonged antitumor activity and could effectively eradicate metastases in a TNBC metastasis model, consequently extending survival. Importantly, manipulating the expression of ICOSL on TNBC cells through overexpression or KO significantly influenced the function of ICOS-B7H3-CAR-T cells. This suggests that the level of ICOSL expression on TNBC cells is critical for enhancing the potent antitumor effects of ICOS-B7H3-CAR-T cells.  \nConclusion Overall, our study highlights the potential clinical application of ICOS as a promising strategy for combating TNBC recurrence and metastasis.  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ The success of blocking antibodies targeting CTLA-4 and programmed death receptor 1 in clinic, such as ipilimumab, pembrolizumab, and nivolumab, has aroused excitement due to their notable regression of melanoma and other cancers. Inducible costimulator (ICOS), a member of the CTLA4/CD28 family, displays promise as a costimulatory target for immunotherapy. Howe","cbCaika55S7ecV5u","https://ap.wps.com/l/cbCaika55S7ecV5u","pdf",8397703,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Introduction","[{\"question\":\"What clinical problem does the study address in triple-negative breast cancer?\",\"answer\":\"The study addresses limited eradication of TNBC by conventional therapies, which often leads to systemic recurrence and metastasis and results in poor prognosis and reduced survival.\"},{\"question\":\"How were the ICOS-enhanced CAR-T cells designed and evaluated?\",\"answer\":\"ICOS-enhanced B7H3-CAR-T cells were generated using third-generation CAR-T technology with heightened ICOS expression and targeting B7H3. Their cytotoxicity and durability were tested in TNBC xenograft and metastasis models, including in vitro and in vivo settings.\"},{\"question\":\"What role does ICOSL expression on TNBC cells play?\",\"answer\":\"Elevated ICOSL expression in TNBC tumor tissues correlated with worse survival. Manipulating ICOSL via overexpression or CRISPR/Cas9-mediated knockout significantly altered the function of ICOS-B7H3-CAR-T cells, indicating ICOSL level is critical for enhanced antitumor effects.\"}]","ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis | PDF",1790011251,38]